Skip to main content
Article thumbnail
Location of Repository

Elevated endotoxin levels in non-alcoholic fatty liver disease

By A. L. Harte, Nancy F. da Silva, Steven J. Creely, K. C. McGee, Thomas Billyard, Elham M. Youssef-Elabd, Gyanendra Tripathi, Esmat Ashour, Mohga S. Abdalla, Hayat M. Sharada, Ashraf I. Amin, Alastair D. Burt, Sudhesh Kumar, Christopher Paul Day and P. G. McTernan


Background: Emerging data indicate that gut-derived endotoxin may contribute to low-grade systemic inflammation\ud in insulin resistant states. This study aimed to examine the importance of serum endotoxin and inflammatory markers\ud in non-alcoholic fatty liver disease (NAFLD) patients, with and without type 2 diabetes mellitus (T2DM), and to explore\ud the effect of treatment with a lipase inhibitor, Orlistat, on their inflammatory status.\ud Methods: Fasted serum from 155 patients with biopsy proven NAFLD and 23 control subjects were analysed for\ud endotoxin, soluble CD14 (sCD14), soluble tumour necrosis factor receptor II (sTNFRII) and various metabolic\ud parameters. A subgroup of NAFLD patients were re-assessed 6 and 12 months after treatment with diet alone (n = 6) or\ud diet plus Orlistat (n = 8).\ud Results: Endotoxin levels were significantly higher in patients with NAFLD compared with controls (NAFLD: 10.6(7.8,\ud 14.8) EU/mL; controls: 3.9(3.2, 5.2) EU/mL, p < 0.001); NAFLD alone produced comparable endotoxin levels to T2DM\ud (NAFLD: T2DM: 10.6(5.6, 14.2) EU/mL; non-diabetic: 10.6(8.5, 15.2) EU/mL), whilst a significant correlation between\ud insulin resistance and serum endotoxin was observed (r = 0.27, p = 0.008). Both sCD14 (p < 0.01) and sTNFRII (p < 0.001)\ud increased with severity of fibrosis. A positive correlation was also noted between sTNFRII and sCD14 in the NAFLD\ud subjects (r = 0.29, p = 0.004).\ud Sub-cohort treatment with Orlistat in patients with NAFLD showed significant decreases in ALT (p = 0.006), weight (p\ud = 0.005) and endotoxin (p = 0.004) compared with the NAFLD, non-Orlistat treated control cohort at 6 and 12 months\ud post therapy, respectively.\ud Conclusions: Endotoxin levels were considerably increased in NAFLD patients, with marked increases noted in early\ud stage fibrosis compared with controls. These results suggest elevated endotoxin may serve as an early indicator of\ud potential liver damage, perhaps negating the need for invasive liver biopsy. As endotoxin may promote insulin\ud resistance and inflammation, interventions aimed at reducing endotoxin levels in NAFLD patients may prove beneficial\ud in reducing inflammatory burden

Topics: RC
Publisher: BioMed Central Ltd.
Year: 2010
OAI identifier:

Suggested articles


  1. (2006). Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med doi
  2. (2000). Tiribelli C: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med
  3. (2003). Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology doi
  4. (2004). Hafeezunnisa : Non-alcoholic steatohepatitis in type 2 diabetes mellitus. doi
  5. (2003). H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. doi
  6. (2005). Hotamisligil GS: Inflammation, stress, and diabetes. doi
  7. (2002). Akira S: Toll-like receptors as adjuvant receptors. Biochim Biophys Acta doi
  8. (2000). Mantovani A: Toll-like receptor family and signalling pathway. Biochem Soc Trans doi
  9. (2004). Recent Advances in Alcoholic Liver Disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. doi
  10. (2007). DJ: A high-fat meal induces lowgrade endotoxemia: evidence of a novel mechanism of postprandial inflammation.
  11. (2009). Eckhardt E: Chylomicrons promote intestinal absorption of lipopolysaccharides. doi
  12. (2009). Grieco A: Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease (NAFLD). Hepatology doi
  13. (2007). S: Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. doi
  14. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes doi
  15. (2007). Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. doi
  16. (1999). Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. doi
  17. (1990). Shedding of tumor necrosis factor receptors by activated human neutrophils. doi
  18. (2007). Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. doi
  19. (2003). AM: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology doi
  20. (2008). Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin. doi
  21. (2001). AG: The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut doi
  22. (2008). Keshavarzian A: Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int doi
  23. (2007). RF: TLR4 enhances TGF-beta signaling and hepaticfibrosis. Nat Med doi
  24. (1997). Tobias PS: Cellular binding of soluble CD14 requires lipopolysaccharide (LPS) and LPS-binding protein. doi
  25. (2004). Sánchez-Ibarrola A: Lipopolysaccharide needs soluble CD14 to interact with TLR4 in human monocytes depleted of membrane CD14. Microbes Infect doi
  26. (2008). Varying Importance of Soluble and Membrane CD14 in Endothelial Detection of Lipopolysaccaride. doi
  27. (1996). Looareesuwan S: Elevated levels of soluble CD14 in serum of patients with acute Plasmodium falciparum malaria. Clin Exp Immunol doi
  28. (1997). Garrote JA: Lack of correlation between soluble CDI4 and IL-6 in meningococcal septic shock. Pediatr Allergy Immunol doi
  29. (1998). MV: Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis. Alcohol Alcohol doi
  30. (1995). Pattern of soluble TNF receptors I and II in sepsis. Infection doi
  31. (2006). D: Increased risk of NASH in patients carrying the C(-159)T polymorphism in the CD14 gene promoter region. Gut doi
  32. (2009). Cappuccio FP: Ethnic and sex differences in circulating endotoxin levels: A novel marker of atherosclerotic and cardiovascular risk in a British multi-ethnic population. Atherosclerosis doi
  33. (2009). McTernan PG: Epicardial Adipose Tissue as a Source of Nuclear Factor-{kappa}B and c-Jun N-Terminal Kinase Mediated Inflammation in Patients with Coronary Artery Disease. J Clin Endocrinol Metab doi
  34. (2006). Microbial ecology: human gut microbes associated with obesity. Nature doi
  35. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature doi
  36. (2002). Gasbarrini G: Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology
  37. (2005). Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Dig Dis Sci doi
  38. (2008). Effect of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in South Asian individuals with impaired glucose tolerance. doi
  39. (2005). YH: Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.